Navigating Global Health Policy In A Time Of Disruption

Amid a continuously shifting global landscape, the healthcare industry in the U.S. and EU is facing significant regulatory and legislative changes. In the EU, the Health Technology Assessment Regulation (HTAR) has introduced joint clinical assessments and scientific consultations to create a more harmonized and transparent framework for assessing health technologies. Meanwhile, in the U.S., proposed changes to Medicaid, the Affordable Care Act, and the Inflation Reduction Act threaten to create additional financial burdens on patients, making it more challenging for them to access medications.

These changes underscore the importance of agility and a patient-centered approach. By engaging with patient advocacy groups and prioritizing patient needs in policy discussions, the industry can better position itself to ensure timely access to treatments for patients. To learn more about navigating this complex environment and the specific implications of these policy changes, access the full article.